Antibiotic Treatment for Infected Amputation with CRE and Meropenem Allergy
For an infected amputation site with confirmed CRE in a patient allergic to meropenem, use ceftazidime-avibactam 2.5 g IV every 8 hours infused over 3 hours, combined with metronidazole 500 mg IV every 6 hours for anaerobic coverage. 1
Primary Treatment Recommendation
The 2022 Taiwan guidelines specifically recommend ceftazidime-avibactam for complicated intra-abdominal infections (cIAI) and skin/soft tissue infections caused by CRE 1. Since an infected amputation site represents a complicated skin and soft tissue infection with potential for polymicrobial involvement, this regimen addresses both the CRE pathogen and anaerobic organisms commonly present in surgical site infections.
Dosing Specifics:
- Ceftazidime-avibactam: 2.5 g IV every 8 hours, infused over 3 hours 1
- Metronidazole: 500 mg IV every 6 hours for anaerobic coverage 1
- Duration: 10-14 days, individualized based on source control and clinical response 1
Alternative Options if Ceftazidime-Avibactam Unavailable
Second-Line: Imipenem-Cilastatin-Relebactam
- Dose: 1.25 g IV every 6 hours 1
- Rationale: This is a different carbapenem class than meropenem and may be tolerated if the allergy is not a true IgE-mediated cross-reactive hypersensitivity. However, exercise extreme caution and obtain allergy consultation first 2
Third-Line: Polymyxin-Based Combination
If new beta-lactam/beta-lactamase inhibitors are unavailable:
- Colistin: 5 mg CBA/kg IV loading dose, then 2.5 mg CBA × (1.5 × CrCl + 30) IV every 12 hours 1
- Plus Tigecycline: 100 mg IV loading dose, then 50 mg IV every 12 hours 1
- Warning: Polymyxin-based regimens have higher nephrotoxicity risk and should be reserved for situations where newer agents are unavailable 1
Fourth-Line: Tigecycline Monotherapy
- Dose: 100 mg IV loading dose, then 50 mg IV every 12 hours 1
- Important caveat: Tigecycline has lower serum concentrations and should NOT be used for bloodstream infections 2. Only consider for localized soft tissue infection without bacteremia
Critical Management Considerations
Mandatory Actions:
- Infectious disease consultation is strongly recommended for all MDRO infections 1
- Obtain susceptibility testing to confirm activity of chosen agent against the specific CRE isolate 1
- Determine carbapenemase type: If metallo-beta-lactamase (MBL) is present, ceftazidime-avibactam will NOT work 2, 3
- For MBL-producing CRE: Consider cefiderocol or aztreonam-ceftazidime-avibactam combination 2
Source Control:
Adequate surgical debridement is essential for infected amputation sites. Antibiotics alone are insufficient without proper source control 1
Allergy Clarification:
Critical: Determine the nature of the meropenem allergy:
- If immediate hypersensitivity (anaphylaxis, angioedema): Avoid ALL carbapenems including imipenem-relebactam 4
- If non-IgE mediated (rash, GI intolerance): Other carbapenems may be considered with caution 4
- The cross-reactivity between meropenem and other beta-lactams is variable; allergy consultation is prudent
Monitoring Parameters
- Renal function: Especially if using polymyxins or aminoglycosides 5
- Clinical response: Assess wound healing, resolution of erythema, drainage, and systemic signs of infection
- Repeat cultures: If no improvement by 48-72 hours to assess for treatment-emergent resistance 6
Common Pitfalls to Avoid
- Do NOT use tigecycline monotherapy if bacteremia is present or suspected 1, 2
- Do NOT assume all CRE will respond to ceftazidime-avibactam: MBL producers require different therapy 3
- Do NOT delay source control: Antibiotics are adjunctive to surgical management in infected amputation sites
- Do NOT use prolonged courses without reassessment: 10-14 days is typically sufficient with adequate source control 1
The evidence strongly supports ceftazidime-avibactam as first-line therapy for CRE soft tissue infections in patients who cannot receive meropenem, with the critical caveat that susceptibility must be confirmed and MBL must be ruled out.